A Vaccine Made From a Person's Own Immune Cells for Brain Tumors
Official title: Immune Modulatory DC Vaccine Against Brain Tumor
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests a vaccine built from a person's own immune cells.
Read our full plain-language summary
What the trial team says
This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The treatment uses immunomodulatory vaccine generated by autologous dendritic cells (DCs) pulsed with genetically modified tumor cells or tumor-related antigens including neoantigens to inject into patients. Vaccine-induced T cell responses have been associated with improved survival. The study will evaluate the safety and potential benefit of the novel immunomodulatory DC vaccines.
Key facts
- Registry number
- NCT03914768
- Stage of testing
- Phase 1
- Conditions studied
- Diffuse Intrinsic Pontine Glioma or Glioblastoma
Where it is running
This trial lists 1 site.
-
Guangdong
- Shenzhen Geno-immune Medical Institute (Shenzhen)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.